Abstract Snakebite envenoming causes over 100,000 deaths annually, creating a need for more effective therapies. Traditionally, most preclinical testing relies on murine models with limited translational value. This review highlights the value of large animal models, particularly sheep and pigs, for studying venom toxicokinetics and antibody and small-molecule pharmacokinetics. Implementing clear guidelines and standardized endpoints in large-animal studies could help advance the clinical translation of new snakebite treatments.
Bénard-Valle et al. (Wed,) studied this question.